This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stock Market Today: Risky Complacency Brings Stocks Higher

NEW YORK (TheStreet) -- Major U.S. stock indices settled Monday higher as the markets returned to a state of complacency defined by expectations of extended Federal Reserve support.

The Dow Jones Industrial Average was up 0.46% to 16,569.28. The S&P 500 was up 0.72% to 1,938.99. The Nasdaq tacked on 0.72% to 4,383.89. A confluence of factors including concerns about early Fed tightening rocked the global markets last week, causing the S&P 500 to suffer its worst weekly drop since June 2012 and the Dow to turn negative for the year. But Friday's solid yet still weaker-than-expected jobs number calmed investors by triggering their expectations that the Fed will stand pat on record-low interest rates at least until June 2015.

The widespread expectation is that the Fed will continue to save the day on any hint of weak fundamentals. The markets do not appear to be ready for any type of early Fed tightening.

Even cautionary remarks on excess from Fed Chair Janet Yellen have generally be dismissed. In July she said she's been seeing excess in biotech stocks and other parts of the markets, but investors brushed aside the comments as "unsolicited." Doug Cote, chief market strategist at Voya Investment Management, said that the market ought to have paid attention to the message she was trying to telegraph: the Fed may have to raise rates earlier than expected, and that investors who are far out on the risk curve might be in trouble if they don't start diversifying effectively.

Must Read: Fed Chair Yellen Says Small Biotech Stocks Over-Valued

"The Fed is looking like they're hand is going to be forced," said Cote. "Increasingly the Fed is looking behind the curve due to extraordinarily positive economic data . . . the Fed can't be this far behind the curve," Cote explained. "They're going to have to signal that they're going to have to raise rates sooner than the market is really discounting, probably early next year."

Examples of this "extraordinarily positive" data include last week's 4% annual rate in U.S. second-quarter GDP and 6% when inflation is added in, and the July manufacturing ISM read of over 57. Evidence shows that the Fed coming closer and closer to achieving its dual mandate on inflation and employment.

"To me, what the market did last week was the shot across the bow signaling impending volatility is near, and so I'm taking that as a warning signal that's kind of like a tremor in an earthquake," said Cote.

Carter Worth, chief market technician at Sterne Agee, warns that the market is long overdue for a loss of 5% or more. Such drops usually occurs every 71 days or 3.5 months, according to Worth. It's already been six months since the broader market last saw a 5%-plus decline.

Michael Kors (KORS - Get Report) shares plunged 5.89% to $77.01 after the luxury retail company said revenue jumped 43.4% to $919.2 million vs. the consensus estimate of $851.7 million on popular demand for its handbags and accessories. Steeper discounts, however, cut into margins.

Sixty-six S&P 500 companies are expected to report this week, including 11 consumer discretionary companies and 10 energy companies.

Amgen (AMGN - Get Report) popped 2.47% to $128.65 after the biotech company said that its blood cancer treatment met primary goals in a late-stage trial. GlaxoSmithKline (GSK - Get Report) gained 1.04% to $48.53 after the drug maker received a boost from a decision by Express Scripts (ESRX - Get Report), the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug Advair as an approved drug in 2015, Reuters reports. Groupon (GRPN - Get Report) added on 8.67% to $7.02 in anticipation of its second-quarter earnings report. Groupon will report its second quarter earnings after the market close on Tuesday, August 5. Analysts surveyed by FactSet expect the company to post earnings of a penny a share and revenue of $60.87 million for the second quarter.

-- By Andrea Tse in New York

Follow @AndreaTTse

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMGN $153.52 0.00%
ESRX $88.94 0.00%
GRPN $5.03 0.00%
GSK $41.65 0.00%
KORS $42.09 0.00%

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.11 +5.48 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs